By Maggie Fick and Diana Novak Jones LONDON (Reuters) -In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and ...

号称千亿美元规模的减肥药市场已然是一片红海，而各大主流减肥药的产品效果都有何区别？从双雄争霸到百花齐放，减肥药市场上新增了哪些玩家？面临合作翻车、专利即将到期等多重夹击的诺和诺德临场换帅，但资本会认可这位新CEO吗？

Hims & Hers Health ( NYSE: HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s ...

This article covers key health news including Primary Health Properties securing a takeover bid for Assura, Novo Nordisk's ...

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

What Happened? Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 3.6% in the afternoon session after the ...

据悉，司美格鲁肽在加拿大受到两重专利保护。首先是数据独占权，加拿大规定药物获批后8年内禁止任何人尝试仿制。这一保护自2018年生效，并于2026年1月到期；另一项则是诺和诺德主动不再维持的专利，这项保护本应在2026年3月到期，但实际上已经于2020 ...

Hims & Hers Health, Inc. (NYSE:HIMS)首席执行官Andrew Dudum于2025年7月16日共计出售了49,826股A类普通股，总价值约250万美元。这些交易分三次执行，价格在50.237美元至50.8213美元之间。 根据向美国证券交易委员会提交的Form 4文件显示，Dudum直接以平均50.579美元的价格出售了2,792股，个别价格在50.47美元至50 ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...